CNB Bank bought a new stake in Becton Dickinson and Co (NYSE:BDX) in the 4th quarter, according to its most recent filing with the SEC. The fund bought 2,335 shares of the medical instruments supplier’s stock, valued at approximately $500,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of BDX. Renaissance Technologies LLC lifted its stake in shares of Becton Dickinson and by 1,192.1% in the 4th quarter. Renaissance Technologies LLC now owns 2,074,503 shares of the medical instruments supplier’s stock valued at $444,068,000 after purchasing an additional 1,913,952 shares during the period. BlackRock Inc. lifted its stake in shares of Becton Dickinson and by 6.0% in the 4th quarter. BlackRock Inc. now owns 18,811,302 shares of the medical instruments supplier’s stock valued at $4,026,750,000 after purchasing an additional 1,071,288 shares during the period. Amundi Pioneer Asset Management Inc. lifted its stake in shares of Becton Dickinson and by 332.3% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 559,551 shares of the medical instruments supplier’s stock valued at $119,776,000 after purchasing an additional 430,127 shares during the period. Atlantic Trust Group LLC lifted its stake in shares of Becton Dickinson and by 597.3% in the 3rd quarter. Atlantic Trust Group LLC now owns 451,035 shares of the medical instruments supplier’s stock valued at $88,381,000 after purchasing an additional 386,349 shares during the period. Finally, DSM Capital Partners LLC acquired a new position in shares of Becton Dickinson and in the 3rd quarter valued at $75,155,000. Hedge funds and other institutional investors own 83.35% of the company’s stock.

How to Become a New Pot Stock Millionaire

Several research firms recently issued reports on BDX. Zacks Investment Research upgraded shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $259.00 target price for the company in a research note on Friday, January 19th. Bank of America reiterated a “buy” rating and issued a $260.00 target price on shares of Becton Dickinson and in a research note on Friday, January 19th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $260.00 target price (up from $223.00) on shares of Becton Dickinson and in a research note on Tuesday, February 6th. Morgan Stanley upped their price objective on shares of Becton Dickinson and from $245.00 to $250.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 7th. Finally, KeyCorp started coverage on shares of Becton Dickinson and in a research report on Friday, January 5th. They set an “overweight” rating and a $260.00 price objective for the company. Six investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $238.00.

Shares of Becton Dickinson and stock opened at $218.50 on Thursday. The company has a market cap of $58,546.72, a PE ratio of 22.81, a PEG ratio of 1.60 and a beta of 1.18. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.54 and a quick ratio of 0.93. Becton Dickinson and Co has a 12-month low of $175.66 and a 12-month high of $248.39.

Becton Dickinson and (NYSE:BDX) last issued its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, beating the Zacks’ consensus estimate of $2.41 by $0.07. The business had revenue of $3.08 billion during the quarter, compared to analysts’ expectations of $3.05 billion. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the business earned $2.33 earnings per share. sell-side analysts anticipate that Becton Dickinson and Co will post 10.94 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Friday, March 9th will be given a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.37%. The ex-dividend date is Thursday, March 8th. Becton Dickinson and’s dividend payout ratio (DPR) is 229.01%.

In other news, Director Timothy M. Ring sold 269,661 shares of the stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $217.82, for a total value of $58,737,559.02. Following the completion of the sale, the director now directly owns 295,753 shares in the company, valued at $64,420,918.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Thomas E. Polen, Jr. sold 1,877 shares of the stock in a transaction dated Tuesday, March 13th. The shares were sold at an average price of $227.00, for a total transaction of $426,079.00. Following the completion of the sale, the executive vice president now owns 15,387 shares of the company’s stock, valued at $3,492,849. The disclosure for this sale can be found here. Insiders sold 281,108 shares of company stock valued at $61,321,396 over the last quarter. Company insiders own 1.00% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/cnb-bank-takes-position-in-becton-dickinson-and-co-bdx/1955411.html.

About Becton Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.